Newcells Biotech in partnership with Newcastle University has been awarded further funding from the NC3R CRACK IT project to create 3D retinal organoids that more closely recapitulate the structure and function of the human retina.
Current cell assays for in vitro screening are based on genetically modified cell lines which are crude models of human biology.
The discovery in 2007 that cells isolated from mature human tissues can be reprogrammed into cells that show pluripotency was a major breakthrough in stem cell science.
Led by Dr Colin Brown, Newcells Biotech has licensed-in an in vitro ADMET assay platform from Newcastle University to determine how new drugs are transported by the kidney.
Newcells Biotech has joined the StemBANCC project, a pan-EU consortium made up of major pharmaceutical and academe groups.
Newcells Biotech have been awarded a grant to employ a PhD student to help develop models of the human lung from iPSCs.
Newcells Biotech has been successful in partnering with Newcastle University to receive funding in a £100K phase I NC3R CRACK IT project to develop a new skin metabolism model using iPSC derived skin cells.
Newcells Biotech Ltd has signed a patent license agreement with ID Pharma Co., Ltd to license and commercialise ID Pharma Co., Ltd patented technologies in the Sendai virus vectors for reprogramming cells to induced pluripotent stem cells (iPSCs).
Newcells Biotech Ltd has signed a patent license agreement with iPS Academia Japan, Inc. to license and commercialise Kyoto University’s patented technologies in the field of induced pluripotent stem cells (iPSCs).
